. Author manuscript; available in PMC: 2019 Nov 1.

Published in final edited form as: Int J Hyperthermia. 2018 Apr 24;34(7):934–942. doi: 10.1080/02656736.2018.1462535

Table 2.

Summary of changes in serum, liver, and distant tumor HGF and VEGF levels for variable hepatic RF ablation without and with adjuvant micellar quercetin therapies.

	IL-6 at 6h (pg/ml)		HGF at 72h (pg/ml)		VEGF at 72h (pg/ml)
Treatment	Liver	Serum	Liver	Serum	Liver
Sham	2,189 ± 106	264 ± 7	21,758 ± 961	2,851 ± 208	7,536 ± 127
Low / 60°Cx10min	2,956 ± 265^*	452 ± 8^*	33,619 ± 1110^*	3,987 ± 47^*	13,036 ± 1214^*
High / 90°C x2min	2,486 ± 72^*	348 ±17^*	25,453 ± 752^*	3,537 ± 202^*	8,925 ± 464^*
Treatment with adjuvant micellar quercetin
Sham / MQ	2,167 ± 134	262 ± 9	22,175 ± 220	2,884 ± 317	7,703 ± 293
Low / 60°Cx10min / MQ	2,903 ± 108^*	442 ±18^*	22,092 ± 507^¥	2,756 ± 276^¥	9,528 ± 821^¥
High / 90°C x2min / MQ	2,503 ± 60^*	359 ±19^*	21,897 ± 1329^¥	2,554 ± 225^¥	8,036 ± 699

p<0.05 when compared to sham group

^**

pre-treatment growth rates same for each MQ arm

^¥

p<0.05 when compared to corresponding RFA alone arms in two-tailed T-test